# EDGAR Filing Document

**Accession Number:** 0001804591
**File Stem:** 0001193125-25-141090
**Filing Date:** 2025-6
**Character Count:** 28593
**Document Hash:** 34b1cf6128db407818b0fa5abd121745
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-141090.hdr.sgml**: 20250616

**ACCESSION NUMBER**: 0001193125-25-141090

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250613

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Termination of a Material Definitive Agreement

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250616

**DATE AS OF CHANGE**: 20250616

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** 23andMe Holding Co.
- **CENTRAL INDEX KEY:** 0001804591
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 871240344
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39587
- **FILM NUMBER:** 251048516

**BUSINESS ADDRESS:**
- **STREET 1:** 870 MARKET STREET
- **STREET 2:** ROOM 415
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94102
- **BUSINESS PHONE:** (650) 938-6300

**MAIL ADDRESS:**
- **STREET 1:** 870 MARKET STREET
- **STREET 2:** ROOM 415
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94102

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VG Acquisition Corp.
- **DATE OF NAME CHANGE:** 20200915

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Virgin Group Acquisition Corp.
- **DATE OF NAME CHANGE:** 20200909

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Bleecker Street Acquisition Corp.
- **DATE OF NAME CHANGE:** 20200225

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): June 13, 2025

## 23andMe Holding Co.

#### (Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39587** | **87-1240344** |
| **(State or other jurisdiction**<br>**of incorporation)** | **(Commission**<br>**File Number)** | **(IRS Employer**<br>**Identification No.)** |

---

#### 870 Market Street, Room 415

#### San Francisco, California 94102

#### (Address of principal executive offices, including zip code)

#### Registrant's telephone number, including area code: (650) 938-6300
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange**<br>**on which registered** |
| Class A Common Stock, $0.0001 par value per share**<sup>1</sup>** |  |  |

---

(1) On June 6, 2025, the Company filed a Form 25 with the Securities and Exchange Commission to remove the Class A common stock from listing and registration on Nasdaq. The delisting will be effective ten days after the filing of the Form 25. The deregistration of the Class A common stock under Section 12(b) of the Securities Exchange Act of 1934, as amended, will be effective 90 days after the filing of the Form 25. The Class A common stock began trading on the OTC Pink Market on March 31, 2025 under the symbol "MEHCQ".

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 1.01** | **Entry into a Material Definitive Agreement.** |

---

As previously disclosed, on March 23, 2025, 23andMe Holding Co., a Delaware corporation (the "Company"), and certain of its subsidiaries (collectively, the "Filing Subsidiaries" and, together with the Company, the "Debtors") filed voluntary petitions seeking relief under Chapter 11 of Title 11 of the United States Bankruptcy Code (the "Bankruptcy Code") in the United States Bankruptcy Court (the "Court") for the Eastern District of Missouri (the "Chapter 11 Cases").

As previously announced, the Debtors conducted an auction for the sale of all or substantially all of the Debtors' assets. At the conclusion of the auction, on May 17, 2025, the Debtors selected (i) Regeneron Pharmaceuticals, Inc., a New York corporation ("Regeneron"), as the successful bidder for substantially all of the Debtors' assets (the "Assets") and (ii) TTAM Research Institute, a California nonprofit public benefit corporation ("TTAM"), as the next-highest or otherwise second-best bidder for the Assets. On May 17, 2025, the Debtors and Regeneron entered into an Asset Purchase Agreement (the "Regeneron Asset Purchase Agreement"), pursuant to which Regeneron agreed to acquire the Assets, excluding the Excluded Assets (as defined in the Regeneron Asset Purchase Agreement), free and clear of liens, claims, encumbrances, and other interests other than certain permitted encumbrances, to assume certain specified liabilities of the Debtors, and to pay amounts necessary to cure defaults and related losses, if any, under contracts to be assumed and assigned to Regeneron, for a total purchase price of $256.0 million in cash and the assumption of the liabilities.

Following the entry into the Regeneron Asset Purchase Agreement, TTAM submitted a bid with the purchase price of $305.0 million. TTAM is an affiliate of Anne Wojcicki, the Company's co-founder, former chief executive officer, and current member of the Company's Board of Directors. On June 4, 2025, the Debtors, TTAM and Regeneron agreed to a framework to facilitate another round of bidding, where the starting bid would be TTAM's purchase price of $305.0 million in cash. The Debtors, Regeneron and TTAM conducted another round of bidding and on June 13, 2025, the Debtors selected TTAM as the winning bidder for the Assets with the purchase price of $305.0 million in cash and Regeneron as the next-highest or otherwise second-best bidder for the Assets for a purchase price of $151.0 million in cash.

On June 13, 2025, the Debtors and TTAM entered into the Asset Purchase Agreement (the "TTAM Asset Purchase Agreement"), pursuant to which TTAM has agreed to acquire the Assets, excluding the Excluded Assets (as defined in the TTAM Asset Purchase Agreement), free and clear of liens, claims, encumbrances, and other interests other than certain permitted encumbrances, to assume certain specified liabilities of the Debtors, and to pay amounts necessary to cure defaults and related losses, if any, under contracts to be assumed and assigned to TTAM (such assumed liabilities and cure payments, the "Liabilities"). TTAM will acquire the Assets for a total purchase price of $305.0 million in cash, in addition to the assumption and payment of the Liabilities, subject to the terms and conditions set forth in the TTAM Asset Purchase Agreement (such transaction contemplated by the TTAM Asset Purchase Agreement, the "Transaction"). In addition, TTAM agreed to serve as a stalking horse sponsor of a chapter 11 plan to acquire the Company's telehealth services business that provides medical care, pharmacy fulfillment, and the lab and test ordering services operated by Lemonaid Health, Inc. (the "Excluded Business") for an aggregate purchase price of $2.5 million. Excluded Assets comprise primarily of the Excluded Business. On June 13, 2025, the Debtors filed the Notice of Winning Bidder with Respect to the Final Proposal Procedures to Acquire the Debtors' Assets (the "Winning Bidder Notice") with the Court. A copy of the TTAM Asset Purchase Agreement is attached to the Winning Bidder Notice as Exhibit A.

The TTAM Asset Purchase Agreement contains customary representations, warranties and covenants of the parties for a transaction involving the acquisition of assets from a debtor in bankruptcy. None of the representations, warranties or pre-closing covenants contained in the TTAM Asset Purchase Agreement survive the closing of the Transaction, nor does the TTAM Asset Purchase Agreement provide for indemnification for any breach of such representations, warranties or covenants.

The TTAM Asset Purchase Agreement remains subject to approval by the Court and customary closing conditions. Additionally, the TTAM Asset Purchase Agreement contains certain termination rights for TTAM and the Debtors, including the right to terminate the TTAM Asset Purchase Agreement if the closing date for the Transaction has not

------

occurred on or prior to September 1, 2025 (or December 1, 2025, in certain circumstances), if the Court dismisses or converts the Chapter 11 Cases to a case under Chapter 7 of the Bankruptcy Code before the closing of the Transaction or if the Court denies approval of the Sale or Sale Order (each as defined in the TTAM Asset Purchase Agreement).

A hearing before the Court to consider approval of the TTAM Asset Purchase Agreement and the Transaction is currently scheduled for June 17, 2025. If the Transaction with TTAM is not consummated, the Debtors will seek authorization of the Court to consummate the transactions contemplated by the Regeneron Asset Purchase Agreement, which is subject to similar approvals.

Pursuant to the TTAM Asset Purchase Agreement, TTAM shall make an earnest deposit of $30.5 million in an escrow account, of which it has already deposited $14.6 million, which amount will either (i) be credited against the purchase price payable at the closing date and released to the Debtors, or (ii) be released to Debtors or TTAM, in each case, subject to and in accordance with the terms of the TTAM Asset Purchase Agreement.

---

| | |
|:---|:---|
| **Item 1.02** | **Termination of a Material Definitive Agreement.** |

---

The description of the Regeneron Asset Purchase Agreement set forth in Item 1.01 of this Current Report is incorporated herein by reference. On June 13, 2025, the Debtors terminated the Regeneron Asset Purchase Agreement.

Regeneron remains a back-up bidder for the Assets for a purchase price of $151.0 million in cash pursuant to a Court order. The Debtors will retain $15.1 million of the earnest deposit made by Regeneron to support its back-up bid and release the remainder to Regeneron.

---

| | |
|:---|:---|
| **Item 8.01** | **Other Events.** |

---

On June 13, 2025, the Company issued a press release announcing the selection of TTAM as the winning bidder for the Assets and the entry into the TTAM Asset Purchase Agreement. A copy of the press release is attached hereto as exhibit 99.1 and incorporated by reference herein.

#### Additional Information on the Chapter 11 Cases
Court filings and information about the Chapter 11 Cases, including the TTAM Asset Purchase Agreement, can be found at a website maintained by the Company's claims agent Kroll at https://restructuring.ra.kroll.com/23andMe, by calling (888) 367-7556, or by sending an email to 23andMeInfo@ra.kroll.com. The documents and other information available via website or elsewhere are not part of this Current Report on Form 8-K and shall not be deemed incorporated herein.

#### Cautionary Note Regarding the Company's Common Stock
The Company cautions that trading in the Company's Class A common stock, $0.0001 par value per share (the "Common Stock") during the pendency of the Chapter 11 Cases is highly speculative and poses substantial risks. Trading prices for the Company's Common Stock may bear little or no relationship to the actual recovery, if any, by holders of the Common Stock in the Chapter 11 Cases. The Company cannot assure investors of the liquidity of an active trading market, the ability to sell shares of the Common Stock when desired, or the prices that an investor may obtain for the shares of the Common Stock.

#### Cautionary Note Regarding Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements, other than statements of historical fact, included or incorporated in this document are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," "predicts," "continue," "will," "schedule," and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-

------

looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on the Company's current expectations and projections about future events and various assumptions. The Company cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on the Company's forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of the Company), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements, which could include the following: risks and uncertainties relating to the Chapter 11 Cases, including but not limited to, the Company's ability to obtain Court approval with respect to motions in the Chapter 11 Cases, the effects of the Chapter 11 Cases on the Company and on the interests of various constituents, Court rulings in the Chapter 11 Cases and the outcome of the Chapter 11 Cases in general, the Debtors' ability to complete the sale of substantially all of their assets under Section 363 of the Bankruptcy Code, the length of time the Company will operate under the Chapter 11 Cases, risks associated with any third-party motions in the Chapter 11 Cases, the potential adverse effects of the Chapter 11 Cases on the Company's liquidity or results of operations and increased legal and other professional costs necessary to execute the Company's reorganization; whether the Company will emerge, in whole or in part, from the Chapter 11 Cases as a going concern; trading price and volatility of the Common Stock; and the continuation of trading of the Common Stock on the OTC Pink Market, including whether broker-dealers will continue to provide public quotes of the Common Stock on the OTC Pink Market, whether the trading volume of the Common Stock will be sufficient to provide for an efficient trading market, and whether quotes for the Common Stock will continue on this market in the future. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission (the "SEC"), including under Item 1A, "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as filed with the SEC, and as revised and updated by the Company's Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The statements made herein are made as of the date of this document and, except as may be required by law, the Company undertakes no obligation to update them, whether as a result of new information, developments, or otherwise.

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.** |

---

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit** <br>**No.** | **Description of Exhibit** |
| 99.1 | [Press Release of the Company dated June 13, 2025](d75328dex991.htm) |
| 104 | Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **23ANDME HOLDING CO.** | **23ANDME HOLDING CO.** |
| Date: June 16, 2025 | By: | /s/ Joseph Selsavage |
|  |  | Name: Joseph Selsavage |
|  |  | Title: Interim Chief Executive Officer, and Chief Financial and Accounting Officer |

---

## Exhibit 99.1

**Exhibit 99.1** 

**23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process** 

*TTAM Commits to Comply with Company's Privacy Policy and All Applicable Laws* 

*TTAM Commits to Adopting Additional Consumer Protections and Privacy Safeguards to Enhance Protections for Customer Data and Privacy* 

*No Changes to 23andMe's Privacy Policy or Consumer Genome Services* 

*Transaction Subject to Court Approval* 

**SAN FRANCISCO — June 13, 2025 —** 23andMe Holding Co. ("23andMe" or the "Company") (OTC: MEHCQ), a leading human genetics and biotechnology company, today announced that it has entered into a definitive agreement with TTAM Research Institute ("TTAM"), a nonprofit public benefit corporation based in California and led by 23andMe Co-Founder and former CEO Anne Wojcicki, for the sale of substantially all of the Company's assets, including the Personal Genome Service (PGS) and Research Services business lines and the Lemonaid Health business, for a purchase price of $305 million.

The agreement with TTAM is the result of a final round of bidding that occurred earlier today between TTAM and Regeneron Pharmaceuticals, Inc. ("Regeneron") (NASDAQ: REGN). The final round of bidding was conducted according to procedures approved by the U.S. Bankruptcy Court for the Eastern District of Missouri (the "Court") and designed to allow the Special Committee of 23andMe's Board of Directors to obtain, consistent with its fiduciary duties, the most value-maximizing transaction for the Company's stakeholders. At the conclusion of the final round of bidding, TTAM was selected as the winning bidder and Regeneron was selected as the backup bidder.

The transaction is aligned with 23andMe's Privacy Statements as TTAM has affirmed its commitment to comply with the Company's privacy policies and applicable law, process all customer personal data in accordance with the consents, privacy policies and statements, terms of service, and notices currently in effect, and have security controls in place designed to protect such data.

In addition, TTAM has made binding commitments to adopt additional consumer protections and privacy safeguards to enhance protections for customer data and privacy, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. **Customer Data Rights:** TTAM will honor 23andMe's existing policies that allow individuals to delete
their account and genetic data and opt-out of research in perpetuity;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. **Customer Notification:** With 23andMe's cooperation, all customers will be emailed at least two
business days before closing with details on TTAM's role, TTAM's commitment to privacy choices, and instructions on how to delete data or opt out of research;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. **Data Transfer Restrictions:** TTAM will not sell or transfer genetic data in connection with a subsequent
bankruptcy or change of control unless the recipient is a qualified domestic entity that adopts TTAM's privacy policies and complies with all laws;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. **Privacy Advisory Board:** Within 90 days of the closing, TTAM will establish a Consumer Privacy Advisory
Board;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. **Privacy Procedures and Reporting:** TTAM will implement privacy procedures, notify customers of material
changes, mitigate data breaches, and prepare annual reports to be made available to Attorneys General upon request;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. **Identity Theft Monitoring:** TTAM will offer customers two years of free Experian identity theft
monitoring; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. **Research and Donations:** TTAM will continue 23andMe's policy of allowing de-identified data to be used for scientific and biomedical research to research scholars at academic universities and other nonprofits and refuse donations from individuals or companies in specified countries.

Upon Court approval of the proposed transaction, the definitive agreement with TTAM will fully replace and nullify the previously announced acquisition and underlying asset purchase agreement with Regeneron to acquire 23andMe for $256 million.

"We are pleased that the competitive bidding process has resulted in significantly more value to our stakeholders while enhancing critical protections around customer privacy, choice and consent with respect to their genetic data," said Mark Jensen, Chair of the Board and member of the Special Committee of the Board of Directors of 23andMe. "As 23andMe's founder, Ms. Wojcicki is well positioned to advance the Company's founding vision of helping people access, understand and gain health benefits through greater understanding of the human genome. We will work to complete the transaction quickly so that 23andMe can begin its next chapter as a nonprofit."

"I am thrilled that TTAM Research Institute will be able to continue the mission of 23andMe to help people access, understand and benefit from the human genome. We believe it is critical that individuals are empowered to have choice and transparency with respect to their genetic data and have the opportunity to continue to learn about their ancestry and health risks as they wish," said Ms. Wojcicki. "The 23andMe community of consented individuals will also have the opportunity to be part of making novel genetic discoveries that improve our knowledge of DNA – the code of life – and the health and wellness of everyone. I remain committed to the 23andMe community and driving forward this mission. The future of healthcare belongs to all of us."

The proposed transaction remains subject to approval by the Bankruptcy Court and customary closing conditions. A Court hearing to consider approval of the transaction is currently scheduled for June 17, 2025, and the transaction is expected to close in the coming weeks.

Additional information regarding 23andMe's Chapter 11 filing, proceedings and claims process is available at <u>https://restructuring.ra.kroll.com/23andMe</u>. Questions about the claims process should be directed to the Company's claims agent, Kroll, at <u>23andMeInfo@ra.kroll.com</u> or by calling (888) 367-7556.

**Advisors** 

Paul, Weiss, Rifkind, Wharton & Garrison LLP and Carmody MacDonald P.C. are serving as legal counsel to 23andMe and Alvarez & Marsal North America, LLC as restructuring advisor. Moelis & Company LLC is serving as investment banker to the Company and the Special Committee of 23andMe's Board of Directors. Reevemark and Scale are serving as communications advisors to the Company.

Skadden, Arps, Slate, Meagher & Flom LLP, Kirkland & Ellis LLP, Arnold & Porter Kaye Scholer LLP and and Quinn Emanuel Urquhart & Sullivan LLP are serving as legal advisors to TTAM Research Institute. TD Cowen LLP is serving as financial advisor to TTAM Research Institute.

------

**About 23andMe** 

23andMe is a genetics-led consumer healthcare and biotechnology company empowering a healthier future. For more information, please visit <u>www.23andme.com</u>.

**About TTAM Research Institute** 

The TTAM Research Institute is a nonprofit medical research organization dedicated to helping scientists and non-scientists join together to unravel the mysteries of DNA—the code of life. TTAM believes everyone should have the opportunity to access their individual genetic code and be empowered to contribute it to scientific research. The TTAM Research Institute was founded and is led by Anne Wojcicki.

**Forward-Looking Statements** 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included or incorporated in this press release are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," "predicts," "continue," "will," "schedule," and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe's current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe's forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements, which could include the following: risks and uncertainties relating to the Company's Chapter 11 case (the "Chapter 11 case"), including but not limited to, the Company's ability to obtain Court approval with respect to motions in the Chapter 11 case, the effects of the Chapter 11 case on the Company and on the interests of various constituents, Court rulings in the Chapter 11 cases and the outcome of the Chapter 11 cases in general, the debtors' ability to complete the sale of substantially all of their assets to Regeneron under Section 363 of the Bankruptcy Code, the length of time the Company will operate under the Chapter 11 case, risks associated with any third-party motions in the Chapter 11 case, the potential adverse effects of the Chapter 11 case on the Company's liquidity or results of operations and increased legal and other professional costs necessary to execute the Company's reorganization; whether the Company will emerge, in whole or in part, from the Chapter 11 case as a going concern; trading price and volatility of the Company's Class A common stock, $0.0001 par value per share (the "Common Stock"); and the continuation of trading of the Common Stock on the OTC Pink Market, including whether broker-dealers will continue to provide public quotes of the Common Stock on the OTC Pink Market, whether the trading volume of the Common Stock will be sufficient to provide for an efficient trading market, and whether quotes for the Common Stock will continue on this market in the future. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission (the "SEC"), including under Item 1A, "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as filed with the SEC, and as revised and updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The statements made herein are made as of the date of this press release and, except as may be required by law, 23andMe undertakes no obligation to update them, whether as a result of new information, developments, or otherwise.

------

**Contact Information**<u> </u>

<u>investors@23andme.com</u>

<u>press@23andme.com</u>